Sugi Predict

Sugi Predict / Compounds / Farnesyl Diphosphate

Farnesyl Diphosphate

Farnesyl Diphosphate

SCHEMBL6066352

C=C(C)CCOP(=O)(O)OP(=O)(O)O.CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O)OP(=O)(O)O.CC(C)=CCC/C(C)=C/COP(=O)(O)OP(=O)(O)O.O=P(O)(O)OP(=O)(O)O

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ FNTA P49354 15/20 0.78
▸ FNTB P49356 13/20 0.78
▸ PGGT1B P53609 6/20 0.78
▸ BTN3A1 O00481 1/20 0.61
▸ GGPS1 O95749 3/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isopentenylpyrophosphate SCHEMBL16767445 1.00 FNTA (0.78) FNTAFNTBPGGT1BBTN3A1GGPS1
Isopentenylpyrophosphate SCHEMBL16767444 1.00 FNTA (0.78) FNTAFNTBPGGT1BBTN3A1GGPS1
Farnesyl Diphosphate SCHEMBL6061708 0.99 FNTA (0.80) FNTAFNTBPGGT1BBTN3A1GGPS1
Geranyl Diphosphate SCHEMBL19971954 0.98 FNTA (0.74) FNTAFNTBPGGT1BBTN3A1GGPS1
Geranyl Diphosphate SCHEMBL16767264 0.98 FNTA (0.74) FNTAFNTBPGGT1BBTN3A1GGPS1
Isopentenylpyrophosphate SCHEMBL28016670 0.93 FNTA (0.70) FNTAFNTBPGGT1BBTN3A1GGPS1
Isopentenylpyrophosphate SCHEMBL28015989 0.93 FNTA (0.70) FNTAFNTBPGGT1BBTN3A1GGPS1
Farnesyl Diphosphate SCHEMBL16987391 0.90 FNTA (0.97) FNTAFNTBPGGT1BBTN3A1
Geranyl Diphosphate SCHEMBL16767263 0.89 FNTA (0.62) FNTAFNTBPGGT1BBTN3A1GGPS1
SCHEMBL25272102 0.88 FNTA (1.00) FNTAFNTBPGGT1BBTN3A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060068456-A1 Methods for screening and identifying compounds BAYER PHARMACEUTICALS CORPORATION (US) 2006-03-30 — — US disclosed
US-6994956-B2 combining with radiolabelled substrate, adding phase-partition scintillation fluid, then incubating within single vessel comprising multiwell plates; for screening compounds for treatment of diabetes, obesity, cardiovascular disease, and cancer BAYER PHARMACEUTICALS CORPORATION (US) 2006-02-07 — — US disclosed
US-20050064531-A1 Methods for screening and identifying compounds BAYER PHARMACEUTICALS CORPORATION (US) 2005-03-24 — — US disclosed